Amendments to the Claims

This Listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound of formula I



(I)

wherein

X is $=CR^0-$ or =N-;

each of R^0, R^1, R^2, R^3 and R^4 independently is hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkyl-C_1-C_8alkyl; hydroxyC_1-C_8alkyl; C_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkoxyC_1-C_8alkyl; arylC_1-C_8alkyl which optionally may be substituted on the ring by hydroxy, C_1-C_8alkoxy, carboxy or C_1-C_8alkoxycarbonyl;

or R^3 and R^4 form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and ~~comprising additionally~~ having 1, 2 or 3 heteroatoms selected from N, O and S;

or each of R^1, R^2 and R^3, independently, is halogen; halo-C_1-C_8alkyl; C_1-C_8alkoxy; halo-C_1-C_8alkoxy; hydroxyC_1-C_8alkoxy; C_1-C_8alkoxyC_1-C_8alkoxy; aryl; arylC_1-C_8alkoxy; heteroaryl; heteroaryl-C_1-C_4alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy; C_2-C_8alkoxycarbonyl; C_2-C_8alkylcarbonyl; -N(C_1-C_8alkyl)C(O) C_1-C_8alkyl; -N(R^{10})R^{11}; -CON(R^{10})R^{11}; -SO_2N(R^{10})R^{11}; or -C_1-C_4-alkylene-SO_2N(R^{10})R^{11}; wherein each of R^{10} and R^{11} independently is hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkyl-C_1-C_8alkyl; C_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkyl; (C_1-C_8alkyl)-carbonyl; arylC_1-C_8alkyl which optionally may be substituted on the ring by hydroxy, C_1-C_8alkoxy, carboxy or C_2-C_8alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;

or R^1 and R^2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl ~~residue~~ group ~~comprising~~ having one or two heteroatoms selected from N, O and S; or

each of R^5 and R^6 independently is hydrogen; halogen; cyano; C_1-C_8alkyl; halo-C_1-C_8alkyl; C_2-C_8alkenyl; C_2-C_8alkynyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkylC_1-C_8alkyl; C_5-C_{10}arylC_1-C_8alkyl;

each of R^7, R^8 and R^9 is independently hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl;

halo-C_1-C_8alkyl; C_1-C_8alkoxy; C_3-C_8cycloalkyl; C_3-C_8cycloalkylC_1-C_8alkyl; arylC_1-C_8alkyl; -Y-R^{12} wherein Y is a direct bond or O and R^{12} is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring ~~comprising~~ having 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; (C_1-C_8alkoxy)-carbonyl; -N(C_{1-8}alkyl)-CO-$NR^{10}R^{11}$; -$CONR^{10}R^{11}$; -$N(R^{10})(R^{11})$; -$SO_2N(R^{10})R^{11}$; R^7 and R^8 or R^8 and R^9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl ~~comprising~~ having 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring;

provided that one of R^1, R^2 or R^3 is -$CON(R^{10})R^{11}$ or-$SO_2N(R^{10})R^{11}$;

in free form or salt form[[.]],

wherein

aryl represents phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl,

heteroaryl is a 5 or 6 membered aromatic heterocyclic ring, optionally condensed to 1 or 2 benzene rings and/or to a further heterocylic ring, and

wherein a heterocyclic ring is a 5 or 6 membered heterocyclic ring being saturated or unsaturated and optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring.

2. (Original) A process for the production of a compound of formula I according to claim 1, comprising the steps of reacting a compound of formula II



(II)

wherein R^1, R^2, R^3, R^4, R^5, R^6 and X are as defined in claim 1, and Y is a leaving group; with a compound of formula III



(III)

wherein R^7, R^8 and R^9 are as defined in claim 1;

and recovering the resulting compound of formula I in free form or in salt form, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.

3. (Cancelled)

4. (Original) A pharmaceutical composition comprising a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers or diluents therefor.

5. (Cancelled)

6. (Cancelled)

7. (Currently Amended) A combination which comprises (a) a therapeutically effective amount of ~~a ZAP-70, FAK and/or Syk inhibitor~~ the compound of claim 1; and (b) a second drug substance.

8. (Currently Amended) A method for treating ~~or preventing a disease or condition in which ZAP-70, FAK and/or Syk tyrosine inhibitor activation plays a role or is implicated~~ acute or chronic rejection of organ or tissue, atheriosclerosis, vascular occlusion, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS disease, cancer, infectious disease, inflammatory disease, or autoimmune disease, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.

9. (Currently Amended) A method for treating ~~or preventing a disease or condition in which ZAP-70, FAK and/or Syk tyrosine inhibitor activation plays a role or is implicated~~ acute or chronic rejection of organ or tissue, atheriosclerosis, vascular occlusion, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS disease, cancer, infectious disease, inflammatory disease, or autoimmune disease, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of ~~a ZAP-70, FAK and/or Syk inhibitor~~ the compound of claim 1 in combination with a second drug substance.